A total of 11,771,252 participants who underwent health check-ups in 2009–2012 were followed. Participants were stratified based on the body mass index categories and metabolic condition:
- Metabolically healthy, Normal-weight (MHNW)
- Metabolically obese, Normal-weight (MONW)
- Metabolically healthy, obese (MHO),
- Metabolically obese, obese (MOO)
Of the study participants, 6,165,051, 1,226,359, 2,312,828, and 2,067,004 subjects were classified into MHNW, MONW, MHO, and MOO group, respectively. Mean BMI was 22.2 in the MHNW group and 27.8 in MOO group. During a 5.4 ± 1.1 years of follow-up visit, 56,552 participants were found to have prostate cancer. Multivariable adjusted HR was 1.143 for MONW group, 1.097 for MHO group, and 1.25 for MOO group, showing MONW group was higher than MHO group. Incidence rate of prostate cancer showed significant correlation to the number of components of metabolic syndrome (Table 1).
Group |
n |
Events |
Duration |
HR (95% C.I.) |
||
Age-adjusted |
Multivariable-adjusted * |
|||||
MHNW |
6,165,051 |
25,408 |
33,344,815 |
1 (Ref.) |
1 (Ref.) |
|
MONW |
1,226,359 |
11,337 |
6,515,983 |
1.143 (1.118, 1.169) |
1.143 (1.118, 1.168) |
|
MHO |
2,312,838 |
7199 |
12,536,988 |
1.109 (1.08, 1.138) |
1.097 (1.068, 1.126) |
|
MOO |
2,067,004 |
12,608 |
11,066,875 |
1.257 (1.231, 1.284) |
1.25 (1.223, 1.277) |
|
Table 1. Association Between Metabolic Status and Incident Prostate Cancer |
Abbreviations: IR, incidence rate; HR, hazard ratio; CI, confidence interval; MHNW, metabolically healthy, normal-weight, MONW; metabolically obese, normal-weight; MHO, metabolically healthy, obese; MOO, metabolically obese, obese.
*Adjusted for age, smoking, alcohol drinking, exercise, and income
In conclusion, this population-based study shows clear evidence of association between metabolic health status and the incidence of prostate cancer. The risk was correlated to the number of components of the metabolic syndrome.
Presented by: Kim J.W, Korea University Guro Hospital, Dept. of Urology, Seoul, Korea, South
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, twitter: @GoldbergHanan at the 2018 European Association of Urology Meeting EAU18, 16-20 March, 2018 Copenhagen, Denmark